MX2009000198A - Formas cristalinas de profarmaco amida de gemcitabina, composiciones y usos del mismo. - Google Patents

Formas cristalinas de profarmaco amida de gemcitabina, composiciones y usos del mismo.

Info

Publication number
MX2009000198A
MX2009000198A MX2009000198A MX2009000198A MX2009000198A MX 2009000198 A MX2009000198 A MX 2009000198A MX 2009000198 A MX2009000198 A MX 2009000198A MX 2009000198 A MX2009000198 A MX 2009000198A MX 2009000198 A MX2009000198 A MX 2009000198A
Authority
MX
Mexico
Prior art keywords
compositions
crystalline forms
amide prodrug
gemcitabine
gemcitabine amide
Prior art date
Application number
MX2009000198A
Other languages
English (en)
Spanish (es)
Inventor
Alexandr Yevgenyevich Oblezov
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2009000198A publication Critical patent/MX2009000198A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
MX2009000198A 2006-06-21 2007-06-20 Formas cristalinas de profarmaco amida de gemcitabina, composiciones y usos del mismo. MX2009000198A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81550806P 2006-06-21 2006-06-21
US81540706P 2006-06-21 2006-06-21
PCT/US2007/071613 WO2007149891A2 (en) 2006-06-21 2007-06-20 Crystalline forms of gemcitabine amide prodrug, compositions and use thereof

Publications (1)

Publication Number Publication Date
MX2009000198A true MX2009000198A (es) 2009-01-22

Family

ID=38670971

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009000198A MX2009000198A (es) 2006-06-21 2007-06-20 Formas cristalinas de profarmaco amida de gemcitabina, composiciones y usos del mismo.

Country Status (11)

Country Link
US (1) US8114854B2 (enExample)
EP (1) EP2043653B1 (enExample)
JP (1) JP5225271B2 (enExample)
KR (1) KR101108407B1 (enExample)
CN (1) CN101448504B (enExample)
AU (1) AU2007261002B2 (enExample)
CA (1) CA2652633C (enExample)
EA (1) EA014909B1 (enExample)
ES (1) ES2446092T3 (enExample)
MX (1) MX2009000198A (enExample)
WO (1) WO2007149891A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2307003A2 (en) * 2008-05-16 2011-04-13 Pharma Mar S.A. Combination therapy with pm00104 and another antitumor agent
NZ590058A (en) * 2008-06-12 2012-08-31 Scinopharm Taiwan Ltd Crystalline polymorphs of gemcitabine base
CN101525361B (zh) 2009-04-21 2010-11-17 济南圣鲁金药物技术开发有限公司 基于吉西他滨结构的前药及其合成方法及应用
CN102432654A (zh) * 2011-09-26 2012-05-02 宋云龙 吉西他滨酰胺衍生物及其制备方法和用途
JP6420247B2 (ja) 2012-11-13 2018-11-07 ボーイエン セラピューティクス，インコーポレイティド ゲムシタビンプロドラッグ及びその使用
US9834576B2 (en) * 2013-10-29 2017-12-05 Otsuka Pharmaceutical Co., Ltd. Synthetic route to 2′-deoxy-2′,2′-difluorotetrahydrouridines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100483256B1 (ko) * 1997-01-24 2005-04-15 콘파마 아에스 젬시타빈 유도체
WO2004041203A2 (en) * 2002-11-04 2004-05-21 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
ES2310860T3 (es) * 2004-12-17 2009-01-16 Eli Lilly And Company Profarmaco amida de gemcitabina, composiciones y uso del mismo.

Also Published As

Publication number Publication date
AU2007261002A1 (en) 2007-12-27
EA200970042A1 (ru) 2009-04-28
WO2007149891A2 (en) 2007-12-27
JP2009541344A (ja) 2009-11-26
EP2043653A2 (en) 2009-04-08
WO2007149891A3 (en) 2008-02-14
US8114854B2 (en) 2012-02-14
EA014909B1 (ru) 2011-02-28
EP2043653B1 (en) 2013-12-25
KR20090033447A (ko) 2009-04-03
CN101448504B (zh) 2012-04-11
AU2007261002B2 (en) 2012-03-08
JP5225271B2 (ja) 2013-07-03
ES2446092T3 (es) 2014-03-06
KR101108407B1 (ko) 2012-01-30
CA2652633C (en) 2014-03-25
CN101448504A (zh) 2009-06-03
US20090203640A1 (en) 2009-08-13
CA2652633A1 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
MY148253A (en) Azaadamantane derivatives and methods of use
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
TW200640924A (en) VEGF-R2 inhibitors and methods
UA97502C2 (ru) Кристаллическая твердая основа разагилина
MX2010006738A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2010006736A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX339476B (es) Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
TW200634023A (en) Amide prodrug of gemcitabine, compositions and use thereof
MX2009002241A (es) Compuestos adecuados para usarse en tintas y tintas que tienen esos compuestos.
MX2010008714A (es) Derivados de amida como moduladores alostericos positivos y metodos de uso de los mismos.
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
WO2009145996A3 (en) Amide derivatives as positive allosteric modulators and methods of use thereof
MX2009013515A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica.
EP2129672A4 (en) ESTER AND CARBAMATE AZAADAMANTANE DERIVATIVES AND METHODS OF USE
BRPI0720050A2 (pt) 6-oxo-1,6-diidropirimidin-2-ilas no tratamento de doenças proliferativas
MY155410A (en) Compositions and devices
SG158091A1 (en) Imidazoazepinone compounds
TN2009000536A1 (en) Novel herbicides
MX2009009490A (es) Profarmacos novedosos.
WO2007149891A3 (en) Crystalline forms of gemcitabine amide prodrug, compositions and use thereof
UA107336C2 (ru) Синтез и солевые формы (r)-5-((e)-2-пирролидин-3-илвинил) пиримидина
MX2009010176A (es) Derivados de aza-adamantano 4-substituidos y metodos de uso de los mismos.
WO2010056585A3 (en) Heteroaryl diamide compounds useful as mmp-13 inhibitors
WO2008153938A3 (en) Epigallocatechin-3-gallate crystal compositions

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration